The invention relates to methods for reducing the level of xenobiotic in an environment by contacting the environment with a composition comprising one or more bacterial strains. The invention also relates to bacterial strains for use in method of reducing the level of xenobiotic in a subject. The invention also relates to compositions comprising one or more bacterial strains.
A61P 39/00 - Agents protecteurs généraux ou antipoisons
C02F 3/00 - Traitement biologique de l'eau, des eaux résiduaires ou des eaux d'égout
C12N 1/00 - Micro-organismes, p.ex. protozoaires; Compositions les contenant; Procédés de culture ou de conservation de micro-organismes, ou de compositions les contenant; Procédés de préparation ou d'isolement d'une composition contenant un micro-organisme; Leurs milieux de culture
C12N 15/00 - Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
A23K 10/18 - Ajout de micro-organismes ou de leurs produits d’extraction, p.ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires de micro-organismes vivants
A61K 31/7004 - Monosaccharides ayant uniquement des atomes de carbone, d'hydrogène et d'oxygène
A61K 31/715 - Polysaccharides, c. à d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques; Leurs dérivés, p.ex. éthers, esters
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
The present invention provides a method of analysing a sample obtained from a subject having or suspected of having a somatic disease state, the method comprising: (a) providing a tissue, proximal or distal sample of limited quantity, such as a cell-free DNA (cfDNA)-containing sample obtained from the subject and performing methylation sequencing of at least 10 predetermined genomic regions, wherein said methylation sequencing may comprise a non-destructive, enzyme-based conversion method to differentiate unmethylated cytosine from 5-methylcytosine and/or 5- hydroxymethylcytosine; (b) generating metrics from the methylation sequencing reads in step (a) that represent one or both of (i) a measure of the degree to which the methylation observed within a sequencing read is similar to a previously determined disease methylation signal, said measure comprising a read rating generated by providing a vector of methylation states for each methylation sequencing read and summing the information content of all methylation states that are concordant with the methylation state for the same region previously determined in a one or more disease samples; and (ii) a measure of intra-read methylation heterogeneity; and (c) integrating the metrics generated in step (b) across the at least 10 predetermined genomic regions to obtain a global measure of disease-originating cfDNA in the sample obtained from the subject. Related methods and systems for use in performing the methods are also provided.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
G16B 20/20 - Détection d’allèles ou de variantes, p. ex. détection de polymorphisme d’un seul nucléotide
A formed sheet metal structure is manufactured from a sheet metal workpiece (1, 101). A main anvil tool (10, 110) constrains the first surface (3, 103) of the sheet metal workpiece. The workpiece is bent to form a first basal region (50, 150) and a second basal region (60, 160) with a bend (56, 156) between them. A first auxiliary forming tool (30) deforms first and second sidewall portions (51, 61, 151, 161) with respect to the first and second basal regions (50, 60, 150, 160) thereby to form a first fold region (55, 165) in the sheet metal workpiece (1, 101) between the first sidewall portion (51, 151) and the second sidewall portion (61, 161). Progressively sliding the first auxiliary forming tool (30) along the first fold region (55, 165) causes shear material transfer in the first fold region (55, 165) to further deform the first fold region (55, 165).
B21D 5/01 - Cintrage des tôles le long de lignes droites, p.ex. pour former un pli simple entre des marteaux et des enclumes ou butées
B21D 5/04 - Cintrage des tôles le long de lignes droites, p.ex. pour former un pli simple sur des presses particulières avec fixation d'un côté de la pièce
A housing for sample collection is disclosed. The housing comprises an actuating member configured to move between a first position and a second position, a sample collector and an assay component. In the first position the sample collector is in contact with the assay component and in the second position the sample collector is separated from the assay component and configured to collect a sample.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p.ex. verrerie de laboratoire; Compte-gouttes
A61B 5/151 - Dispositifs de prélèvement d'échantillons de sang spécialement adaptés pour le prélèvement d'échantillons de sang capillaire, p.ex. par des lancettes
B01L 9/00 - Dispositifs de support; Dispositifs de serrage
5.
ABSORPTION INDUCED CALORIC EFFECTS AND USES THEREOF
The present invention relates to use of a fluid to drive a phase transition induced by absorption/desorption of the fluid into and out of the caloric material. A method is providing in which a sorptiocaloric material is contacted with a fluid such that the fluid is absorbed into and at least partially throughout the sorptiocaloric material to induce a phase transition and heat is permitted to flow to or from the sorptiocaloric material. The fluid is then released and is desorbed out of the sorptiocaloric material to induce the reverse phase transition and reverse heat flow. The sorptiocaloric phase transition is capable of very large latent heats under ambient conditions making it potentially useful in conventional cooling and heating applications as well as thermal storage.
F25B 17/08 - Machines, installations ou systèmes à sorption, à marche discontinue, p.ex. à absorption ou à adsorption l'absorbant ou l'adsorbant étant un solide, p.ex. du sel
B01J 20/22 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance organique
C09K 5/04 - Substances qui subissent un changement d'état physique lors de leur utilisation le changement d'état se faisant par passage de l'état liquide à l'état vapeur ou vice versa
An optical element comprising a first wavelength band filter film including a diffractive optical structure, wherein the diffractive optical structure diffracts light including light in a first wavelength band so as to form a first array of optical focal points. The wavelength band filter film selectively performs one of reflecting and transmitting the light in the first wavelength band and selectively performs the other of reflecting and transmitting light outside the first wavelength band.
G02B 1/00 - OPTIQUE ÉLÉMENTS, SYSTÈMES OU APPAREILS OPTIQUES Éléments optiques caractérisés par la substance dont ils sont faits; Revêtements optiques pour éléments optiques
LRR are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein, to processes for synthesising these compounds and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. quinolizines, naphtyridines, berbérine, vincamine
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
LRR are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein, to processes for synthesising these compounds and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. quinolizines, naphtyridines, berbérine, vincamine
Provided are compounds of the Formula II, and salts, hydrates and solvates thereof: (Formula (II) wherein R is as defined in the specification. The compounds are prodrugs of inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the prodrugs defined herein and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. quinolizines, naphtyridines, berbérine, vincamine
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: I wherein Q1, R1, Ra, Rb, Rc, Rd, Re, A1 and A2 are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 413/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. quinolizines, naphtyridines, berbérine, vincamine
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
LRR, and any groups associated therewith, are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.
C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 403/14 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
in vitroGATA6SOX17GATA3TFAP2CTFAP2C gene) under a condition in a culture medium allowing the pluripotent stem cells to self-organize into a post-implantation embryo structure. In some embodiments, the pluripotent embryonic stem cells are human pluripotent embryonic stem cells and the generated synthetic embryo is a human embryo.
23344, the composition comprising particles comprising sub- particles, the sub-particles having a mean greatest dimension of from 10 to 300nm. Methods of making such a composition are also described.
H01M 4/14 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif Électrodes pour accumulateurs au plomb
14.
ELECTRODE, MEDICAL DEVICE, SYSTEM AND METHOD OF MANUFACTURE
The present invention provides an electrode having a substrate and a conductive polymer film layer on the exposed surface, the film layer having a capacitance per area of at least 0.5 F/cm2and/or wherein the film layer has a thickness of between 50-1000 µm. A medical device having a plurality of electrodes wherein at least one of the electrodes includes a polymer film layer, the film layer having a capacitance per area of at least 0.5 F/cm2is also provided, as are systems including the medical device, methods of treatment of a spinal cord lesion and methods of manufacturing the electrodes.
The present invention provides an implantable medical device having: a flexible substrate (10); a delivery conduit (20) formed in the flexible substrate and having an inlet and an outlet located at a proximal end of the device, wherein the delivery conduit passes from the inlet to the outlet via a loop at a distal end of the device; and a delivery hole formed in the delivery conduit allowing passage of fluid from the conduit to the exterior of the substrate. Aspects of the invention also provide a system for the delivery of medicament to a patient and a controller (43) for an implantable medical device which is configured to deliver the medicament predominantly by diffusion rather than convection.
A61M 37/00 - Autres appareils pour introduire des agents dans le corps; Percutanisation, c. à d. introduction de médicaments dans le corps par diffusion à travers la peau
16.
A LAYERED STRUCTURE COMPRISING A COMPOSITE THIN SINGLE LAYER DEPOSITED OVER A BASE ELECTROLYTE LAYER FOR AN ELECTROCHEMICAL DEVICE, A PROCESS FOR MANUFACTURING AND USES THEREOF
FUNDACIÓ INSTITUT DE RECERCA EN ENERGIA DE CATALUNYA (Espagne)
INSTITUCIÓ CATALANA DE RECERCA ESTUDIS AVANCATS (Espagne)
CAMBRIDGE ENTERPRISE LTD (CE) (Royaume‑Uni)
Inventeur(s)
Tarancón Rubio, Albert
Baiutti, Federico
Torrell Faro, Marc
Bernadet, Lucile
Alayo Bueno, Nerea
Driscoll, Judith
Wells, Matt
Abrégé
The present invention relates to a layered structure comprising a composite thin single layer deposited over a base electrolyte layer for an electrochemical device. The present invention further relates to a process for manufacturing said layered structure and uses thereof.
H01M 8/1246 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments à combustible; Leur fabrication Éléments à combustible avec électrolytes solides fonctionnant à haute température, p.ex. avec un électrolyte en ZrO2 stabilisé caractérisés par le procédé de fabrication ou par le matériau de l’électrolyte l'électrolyte étant constitué d’oxydes
H01M 8/1253 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments à combustible; Leur fabrication Éléments à combustible avec électrolytes solides fonctionnant à haute température, p.ex. avec un électrolyte en ZrO2 stabilisé caractérisés par le procédé de fabrication ou par le matériau de l’électrolyte l'électrolyte étant constitué d’oxydes l'électrolyte contenant de l’oxyde de zirconium
H01M 8/126 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments à combustible; Leur fabrication Éléments à combustible avec électrolytes solides fonctionnant à haute température, p.ex. avec un électrolyte en ZrO2 stabilisé caractérisés par le procédé de fabrication ou par le matériau de l’électrolyte l'électrolyte étant constitué d’oxydes l'électrolyte contenant de l’oxyde de cérium
H01M 8/1213 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments à combustible; Leur fabrication Éléments à combustible avec électrolytes solides fonctionnant à haute température, p.ex. avec un électrolyte en ZrO2 stabilisé caractérisés par la combinaison électrode/électrolyte ou par le matériau de support
A system is disclosed for scanning a structural object, comprising a mobile scanning device configured to scan the structural object from a plurality of successive locations to generate for each location a respective point cloud representing a respective portion of the structural object; a calculating unit configured to: (i) determine from the point clouds a pose graph comprising estimates of positions of the successive locations in relation to the structural object; and (ii) calculate for each location a respective uncertainty value in the pose graph; and a display configured to display the point clouds and to provide a visual indication for each point cloud of the calculated uncertainty value of the corresponding location in the pose graph.
This invention relates to mapping the binding sites of a test compound within a nucleic acid. The nucleic acid is contacted with a tagged test compound that binds to the nucleic acid or to protein associated with the nucleic acid at one or more locations. The tagged test compound is contacted with a first binding member that specifically binds to the tag and a second binding member that specifically binds to the first binding member and is attached to an activatable nuclease, such that the second binding member binds to first binding member that is bound to the tagged test compound at the one or more binding sites. The nuclease is then activated to cleave the nucleic acid at the binding sites to generate fragments. The sequence of the generated fragments is indicative of the binding sites of the test compound.
The invention relates to a modified stem cell-like cell for use in organ regeneration or repair wherein the modified stem cell-like cell exhibits reduced ion flow through sodium leak channel (NALCN). The invention also relates to an ion channel modulator for use in organ regeneration or repair. The invention further relates to associated methods, for example, a method of repairing or regenerating an organ.
A61K 35/36 - Substances provenant de mammifères; Compositions comprenant des tissus ou des cellules non spécifiés; Compositions comprenant des cellules souches non embryonnaires; Cellules génétiquement modifiées Épiderme; Cellules épithéliales; Kératinocytes; Cellules de Langerhans; Cellules ectodermiques
The present invention relates to a method of spatially barcoding one or more biological molecules located on or within a substrate by using a transposase complex to label the biological molecule of interest with a detection probe which may then give rise to a spatial barcode. Such analysis may include determining the spatial profiling of one or more biological molecules, specifically the spatial analysis of DNA, open chromatin, chromatin features, proteins and/or RNA which may be spatially barcoded by methods of the invention, either alone or in various combinations. The invention further relates to a transposase complex for use in spatially barcoding one or more biological molecules and reagents kits for performing such methods.
The invention relates to methods for modulating the symbiotic relationship between plants, for example legumes, and nitrogen fixing bacteria in the root nodules. The invention also relates to modified plants, for example gene edited plants that have an altered symbiotic relationship with nitrogen fixing bacteria in the root nodules.
22, -OH and -SH, and the protected forms of each, -W- is optionally substituted methylene, such as methylene, and d is a double or single bond, and the salts and solvates thereof
C07C 233/33 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des atomes d'oxygène liés par des liaisons doubles avec le radical hydrocarboné substitué lié à l'atome d'azote du groupe carboxamide par un atome de carbone d'un cycle aromatique à six chaînons
C07C 271/28 - Esters des acides carbamiques ayant des atomes d'oxygène de groupes carbamate liés à des atomes de carbone acycliques avec l'atome d'azote d'au moins un des groupes carbamate lié à un atome de carbone d'un cycle aromatique à six chaînons à un atome de carbone d'un cycle aromatique à six chaînons non condensé
C07H 15/26 - Radicaux acycliques ou carbocycliques substitués par des hétérocycles
C07K 5/00 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminée; Leurs dérivés
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide condensés avec un carbocycle, p.ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p.ex. cannabinols, méthanthéline
A radio/microwave frequency current probe comprising one or more resistive elements electrically connected between a current input region and a current output region, and a stack of layers each comprising a dielectric material. For each of the resistive elements, the current probe further comprises a plurality of conductive paths each separated by one or more of the layers. A first set of the conductive paths are configured to provide a current path between the current input region and the resistive element, while a second set of conductive paths are configured to provide a current path between the resistive element and the current output region. The plurality of conductive paths are arranged such that the first and second sets of conductive paths alternate in the stack of layers. The current probe may also be integrated into current measurement systems.
G01R 1/20 - Modifications des éléments électriques fondamentaux en vue de leur utilisation dans des appareils de mesures électriques; Combinaisons structurelles de ces éléments avec ces appareils
The invention relates to methods of identifying enzymes and methods of screening for optimised enzymes for degrading polymers such as plastics. The invention also relates to polymer degrading enzymes and nucleic acids encoding these enzymes as well as expression cassettes and host cells comprising the nucleic acids. The invention also relates to uses of these enzymes or the host cells comprising the nucleic acids encoding these enzymes to degrade polymers such as plastics. Lastly, the invention also relates to the crystal structure of plastic degrading enzymes and uses of these structures.
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 9/18 - Hydrolases agissant sur les esters d'acides carboxyliques
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12N 15/70 - Vecteurs ou systèmes d'expression spécialement adaptés à E. coli
C12Q 1/34 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une hydrolase
G16B 15/00 - TIC spécialement adaptées à l’analyse de structures moléculaires bidimensionnelles ou tridimensionnelles, p.ex. relations structurelles ou fonctionnelles ou alignement de structures
25.
PROTEINS FOR REGULATION OF SYMBIOTIC NODULE ORGAN IDENTITY
The present invention provides novel DNA molecules and constructs, including their nucleotide sequences, useful for expressing proteins in plants to promote symbiotic infection. The invention also provides plants and plant cells transgenic plants, plant cells, plant parts, seeds, and commodity products comprising the DNA molecules operably linked to heterologous transcribable polynucleotides, along with methods of their use.
Provided herein are antibodies specific for nucleophosmin 1 (NPM1), which are capable of binding to nucleophosmin 1 located on the surface of cells, as well as antibody-drug conjugates (ADCs) comprising such antibodies. Also provided herein are methods of treating cancers in which NPM1 is expressed on the surface of cancer cells, by administering to a subject an NPM1-binding antibody or antibody conjugate described herein and a chemotherapeutic drug.
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
27.
MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMIN 1 AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE
Provided herein are antibodies specific for nucleophosmin 1 (NPM1), which are capable of binding to wild-type and/or mutant nucleophosmin 1 located on the surface of cells. These antibodies, as well as antibody conjugates comprising these antibodies, are useful for the detection and treatment of cancers in which NPM1 is expressed on the surface of cancer cells.
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
The invention provides a ternary complex of a cucurbituril host, such as CB[8], with a first aryl guest and second aryl guest, wherein the first aryl guest is a group within a biomolecule, such as insulin, and the first and second aryl guests are diferent. Also provided is a method of decomplexing the complex, the method comprising the step of treating the complex with a competitor guest, and permiting the competitor guest to displace at least the first aryl guest from the complex.
C07K 1/113 - Procédés généraux de préparation de peptides par modification chimique de peptides précurseurs sans changement de la structure primaire
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
The invention relates to MAT2A inhibitors and/or TSG101 inhibitors for treating or preventing viral infection in a subject. More specifically, the invention relates to MAT2A inhibitors and/or TSG101 inhibitors for treating or preventing viral infections caused by DNA viruses or nuclear replicating viruses. The invention also relates to MAT2A inhibitors and/or TSG101 inhibitors for treating or preventing viral infections caused by RNA viruses.
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. quinolizines, naphtyridines, berbérine, vincamine
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A61P 31/20 - Antiviraux pour le traitement des virus ADN
A61K 31/4439 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. oméprazole
A61K 31/4745 - Quinoléines; Isoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. phénanthrolines
A61K 31/517 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. quinazoline, périmidine
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
The present invention relates to polydopamine co-polymer nanoparticles as defined in the application. The present invention also relates to processes for the preparation of these polydopamine co-polymer nanoparticles, to pharmaceutical compositions comprising them, and to their use in therapy.
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à quatre chaînons, p.ex. taxol
The invention provides an engineered immune cell, wherein the engineered immune cell comprises a gain-of-function mutation in a Cav channel and/or overexpresses an L-type voltage-gated calcium (Cav) channel. Also provided are related engineered immune cells for use in medicine. Also provided are L-type Cav channel agonists for use in a method of stimulating cell killing activity of an immune cell in a subject having a proliferative disorder. Pharmaceutical compositions and methods are also provided.
Broadly speaking, embodiments of the present techniques provide a method, apparatus and system for automatically detecting and correcting errors in manufacturing parameters of a manufacturing process using closed-loop control. Advantageously, the present techniques not only monitor manufacturing parameters but also provide instructions to enable any unacceptable variation in a manufacturing parameter to be corrected during the manufacturing process.
G05B 13/02 - Systèmes de commande adaptatifs, c. à d. systèmes se réglant eux-mêmes automatiquement pour obtenir un rendement optimal suivant un critère prédéterminé électriques
G05B 19/4099 - Usinage de surface ou de courbe, fabrication d'objets en trois dimensions 3D, p.ex. fabrication assistée par ordinateur
33.
COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES
112341x1234xx are defined herein. The present invention also relates to compositions comprising the compounds of formula (I) or formula (X) defined herein, to processes for synthesising these compounds and to their use for the treatment and/or detection of diseases and conditions in which coagulation proteases, in particular APC, flla, fXa, and fXla, are implicated.
C07K 5/103 - Tétrapeptides la chaîne latérale du premier amino-acide étant acyclique, p.ex. Gly, Ala
C07K 5/107 - Tétrapeptides la chaîne latérale du premier amino-acide contenant des carbocycles, p.ex. Phe, Tyr
C07K 5/11 - Tétrapeptides la chaîne latérale du premier amino-acide contenant plus de groupes amino que de groupes carboxyle, ou leurs dérivés, p.ex. Lys, Arg
C07K 5/117 - Tétrapeptides le premier amino-acide étant hétérocyclique, p.ex. Pro, His, Trp
A resistive switching memory device comprises an active layer comprising an ionic conducting material. The active layer is disposed on a substrate. The device further comprises: a first electrode, a second electrode and optionally a first semiconductor layer. One of the first electrode, second electrode and first semiconductor layer, when present, is the substrate for the active layer and wherein the active layer and the first semiconductor layer, when present, contact each other at an interface. The device exhibits hysteretic I-V behaviour to permit switching of the electrical resistance of the device between different resistance states. The active layer is non-epitaxial with respect to the substrate.
H10N 70/00 - Dispositifs à l’état solide sans barrière de potentiel ni de surface, spécialement adaptés au redressement, à l'amplification, à la production d'oscillations ou à la commutation
H10N 70/20 - Dispositifs de commutation multistables, p.ex. memristors
G11C 13/00 - Mémoires numériques caractérisées par l'utilisation d'éléments d'emmagasinage non couverts par les groupes , ou
The invention provides a method of characterising a DNA sample, the method including the steps of: obtaining a mutational catalogue for the sample, wherein a mutational catalogue comprises counts of mutations in a plurality of predetermined categories; obtaining a mutational signatures catalogue comprising a first set of one or more mutational signatures and a second set of one or more mutational signatures; determining a first set of exposures of the sample to the mutational signatures in the first set of mutational signatures; identifying at least one of the mutational signatures in the second set of mutational signatures that is likely to be present in the sample using the results of the determining; and providing an indication of which of the mutational signatures in the mutational signatures catalogue is present in the sample. Methods of providing a mutational signature catalogue, and related systems and products are also described.
LGR5 binding agents, in particular antibodies or fragments thereof which bind to human LGR5, and the use of such binding agents in the treatment of disease, such as cancer and inflammatory disease, and the detection of LGR5.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
A telescope including an optical alignment system. The telescope has a segmented primary mirror and the mirror segments have facets that are used to direct metrology light for aligning the telescope.
G01B 11/27 - Dispositions pour la mesure caractérisées par l'utilisation de techniques optiques pour tester l'alignement des axes pour tester l'alignement des axes
G02B 23/02 - Télescopes ou lunettes d'approche, p.ex. jumelles; Périscopes; Instruments pour voir à l'intérieur de corps creux; Viseurs; Pointage optique ou appareils de visée comprenant des prismes ou des miroirs
The present invention relates to a process for preparing a nanoparticle composition comprising cyanine dye nanoparticles. The present invention also relates to said nanoparticles and their uses for detecting senescent cells and determining senescent burden.
Broadly speaking, embodiments of the present techniques provide a method and apparatus to quickly and cost effectively screen (5100) a large number of semiconductor materials that may be used for optoelectronic devices. Advantageously, the present techniques use photoluminescence efficiency, PLQE, measurements (S102) and time- resolved photoluminescence, TRPL, measurements (S102) of a sample of a semiconductor material to extract (S104, S106) the parameters needed to screen or evaluate the material. This is advantageous because the measurements can be made using techniques and equipment that is readily accessible to many laboratories and therefore, does not require specialised expertise or equipment that is not readily available in research institutions or industry.
G01N 21/84 - Systèmes spécialement adaptés à des applications particulières
G01N 21/31 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique
40.
A MACHINE-READABLE MARKER AND IDENTIFICATION METHOD
Broadly speaking, embodiments of the present techniques provide an optically- or machine-readable fiducial marker for use in nanoscale applications and a method for automatic detection of a marker. Advantageously, the fiducial marker of the present techniques has features which make it resistant to the processing steps of electron beam lithography. Furthermore, the fiducial marker is robust when reproduced at nanoscales and has high information density.
G03F 9/00 - Mise en registre ou positionnement d'originaux, de masques, de trames, de feuilles photographiques, de surfaces texturées, p.ex. automatique
UNITED KINGDOM RESEARCH AND INNOVATION (Royaume‑Uni)
AHREN LP, ACTING BY ITS GENERAL PARTNER AHREN INNOVATION CAPITAL GUERNSEY (GP) LIMITED (Royaume‑Uni)
Inventeur(s)
Mcewan, William Alexander
Mukadam, Aamir Shehab
Miller, Lauren Virginia Clare
Tuck, Benjamin James
Keeling, Sophie Elizabeth
Smith, Annabel Emily
Winter, Gregory Paul
James, Leo C.
Abrégé
The invention provides a ligand comprising a first binding moiety which binds to tau assemblies, and a second binding moiety which is bound by TRIM21 for use in the treatment of neurodegenerative disease in the cytoplasm of a neuronal cell, wherein the ligand is administered extracellularly.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
in vitroin vitro culture of synthetic embryos from mammalian pluripotent stem cells and extra-embryonic stem cells. The methods and compositions described herein can generate synthetic embryos at different developmental stage reaching early organogenesis and beyond. Disclosed herein also include an embryo culturing system and methods of using same.
C12N 5/073 - Cellules ou tissus embryonnaires; Cellules fœtales ou tissus fœtaux
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
This invention relates to a method for codon optimising a target nucleic acid sequence for expression in a host cell. The invention also relates to codon optimised nucleic acids for improved expression in a host cell, and to vectors and host cells comprising codon optimised nucleic acids.
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
Articles comprising a surface and having on said surface a coating comprising microfibrillated cellulose, methods of applying a coating comprising microfibrillated cellulose to a surface, compositions comprising microfibrillated cellulose, and the use of such compositions in methods of preparing an antimicrobial surface coating.
The invention relates to methods and compositions to boost immune responses to both infection and vaccination against and infection. In particular, the present invention is aimed at providing a method to boost immune responses to both infection with an infectious agent and vaccination against an infection with an infectious agent. It is also aimed at providing a treatment of infectious disease and vaccine adjuvant for the prevention of infection with an infectious agent.
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
A61K 31/343 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide condensés avec un carbocycle, p.ex. coumarane, bufaralol, béfunolol, clobenfurol, amiodarone
A61K 31/4045 - Indole-alkylamines; Leurs amides, p.ex. sérotonine, mélatonine
A61K 31/4406 - Pyridines non condensées; Leurs dérivés hydrogénés substituées uniquement en position 3, p.ex. zimeldine
A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
A method for the detection or prognosis of cancer and/or metastasis is provided. Tumour samples may be used to determine the presence of a mutation within the sodium leak channel (NALCN). A risk score of cancer and/or metastasis can be determined based on if the mutation causes a reduction in the pore size of NALCN. A computational model, a composition, and a kit are also provided.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
There is provided a system for the production of ammonia, the system comprising: a reservoir for liquid ammonia or water; a first vessel configured to receive gaseous nitrogen and hydrogen feedstocks, the first vessel comprising an ammonia synthesis catalyst and a first material for storing ammonia, a second vessel adjacent and in direct thermal communication with the first vessel, the second vessel comprising a second material for storing ammonia or water, and being in fluid communication with the reservoir for liquid ammonia or water; a third vessel comprising a third material for storing ammonia and comprising an outlet for recovering ammonia; wherein the system has at least two operating modes, wherein: (i) in a first operating mode for retaining ammonia synthesised on the catalyst the first vessel is not in fluid communication with the third vessel, and (ii) in a second operating mode the first vessel is in fluid communication with the third vessel for passing ammonia to the third material.
The present invention relates to a process of making an adsorbent body, wherein the process comprises the steps of: (a) contacting adsorbent material with an initial mixture to form a solvated adsorbent mixture in a first solvent; (b) removing the first solvent and removing at least some of the first solvent from the solvated adsorbent mixture in the first solvent to form an initial adsorbent body; (c) contacting the initial adsorbent body with a second solvent to form a reduced-binder adsorbent body in a second solvent; and (d) solvent-drying the reduced-binder adsorbent body to form the adsorbent body. The invention further provides an adsorbent body, and the use of said adsorbent body in gas storage.
B01D 15/02 - Procédés de séparation comportant le traitement de liquides par des adsorbants ou des absorbants solides; Appareillages pour ces procédés par des adsorbants en mouvement
B01J 20/20 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone obtenu par des procédés de carbonisation
B01J 20/22 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance organique
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
1-6 1-6 alkyl groups, -L- is a linker and -B is a non-covalent binding group, such that the bifunctional molecule non-covalently binds to the target nucleic acid molecule, and allowing the bifunctional molecule to cleave the target nucleic acid molecule bound thereto. The invention also provides a method of identifying a secondary or tertiary structure within a target nucleic acid, as well as a bifunctional molecule and a bifunctional molecule for use in a method of treatment.
The disclosure relates to methods of investigating protein aggregation reactions, in particular methods for detecting aggregates of a protein that are capable of seeding further protein aggregation. The methods allow not only understanding of aggregation reactions, but also provide means for detecting whether a sample from an individual comprises aggregate seeds.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
FUNDACION DEL SECTOR PUBLICO ESTATAL CENTRO NACIONAL DE (Espagne)
Inventeur(s)
Macintyre, Geoffrey John
Markowetz, Florian
Drews, Ruben Matthias
Hernando Fuster, Bárbara
Abrégé
A method of characterising a DNA sample obtained from a tumour, the method including the steps of: (a) obtaining a tumour copy number profile for the sample, (b) quantifying a set of copy number features of the copy number profile, and (c) determining exposure to one or more signatures of chromosomal instability based on the quantified features. A copy number feature is a metric that characterises a copy number event in a copy number profile. The set of features does not comprise the absolute copy number of segments in the copy number profile. The signatures of chromosomal instability have been obtained by quantifying the set of copy number features in a plurality of tumour samples, and identifying one or more mutational signatures likely to result in the copy number profiles of the plurality of tumour samples. Methods of characterising types of chromosomal instability present in samples, providing a prognosis, identifying a drug target, or identifying a therapy for a subject are also described.
The invention relates to methods for nucleic acid characterisation. In particular, the method of the invention relates to methods for characterising target nucleic acids in a sample.
a22 where a is from 0.0 to 2.0, X is selected from S, Se and Te, and M is a transition metal, such as Ti, Hf, V, Nb, Ta, Mo, W, Tc, Re, Pd or Pt. The method of preparing a lithium sulfur cell comprises: exfoliating a transition metal dichalcogenide to provide a metallic phase, transition metal dichalcogenide of formula (I); assembling a working electrode comprising a film comprising stacked layers of the metallic phase transition metal dichalcogenide and sulfur or a lithium (poly)sulfide; and assembling a lithium sulfur cell comprising the working electrode, a counter electrode, and an electrolyte.
H01M 4/136 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif Électrodes pour accumulateurs à électrolyte non aqueux, p.ex. pour accumulateurs au lithium; Leurs procédés de fabrication Électrodes à base de composés inorganiques autres que les oxydes ou les hydroxydes, p.ex. sulfures, séléniures, tellurures, halogénures ou LiCoFy
H01M 4/1397 - Procédés de fabrication d’électrodes à base de composés inorganiques autres que les oxydes ou les hydroxydes, p.ex. sulfures, séléniures, tellurures, halogénures ou LiCoFy
H01M 4/36 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs
H01M 4/38 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'éléments simples ou d'alliages
H01M 4/62 - Emploi de substances spécifiées inactives comme ingrédients pour les masses actives, p.ex. liants, charges
H01M 4/02 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif
This invention relates to a method of producing hepatocytes comprising introducing a set of transcription factors consisting of HNF1A; HNF6; F0XA3; RORc and ERa into a population of IPSCs, and culturing the population, such that hepatocytes are produced. Methods of producing hepatocytes, hepatocytes produced by the methods and their uses and applications are provided.
An inertial sensor comprising; a central anchor; a proof mass, wherein the proof mass surrounds the central anchor; a flexure; and a plurality of electrodes is disclosed. The flexure has a shape comprising a first plurality of spiral arms, each winding about the central anchor in a first sense, and a second plurality of spiral arms, each winding about the central anchor in a second sense, the second sense being opposite to the first sense Each of the arms are connected between the central anchor and the proof mass. Advantageously, energy lost through anchor losses and thermoelastic dissipation are reduced in this arrangement, resulting in a higher quality factor for the modes of vibration.
G01C 19/5684 - Dispositifs sensibles à la rotation utilisant des masses vibrantes, p.ex. capteurs vibratoires de vitesse angulaire basés sur les forces de Coriolis utilisant le décalage de phase d'un noeud ou d'un anti-noeud de vibration de vibrateurs essentiellement à deux dimensions, p.ex. vibrateurs en forme d'anneau les dispositifs comportant une structure micromécanique
This invention relates to methods for detecting the presence or absence of target nucleic acids in samples by excising and detecting specific target probes.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
The invention relates to a method for coating an electrode active material with a metal oxide, a method for doping an electrode active material, and coated and doped electrode active materials produced by the methods. The coated and doped electrode active materials can be used in electrochemical cells. The method for coating an electrode active material comprises providing a coating composition comprising an organic solvent and a bimetallic alkoxide, depositing the coating composition to the surface of the electrode active material, and calcining the electrode active material to provide a coating of bimetallic oxide on the surface of the electrode active material. Compared to using two separate metal coating precursors, the bimetallic alkoxide acts as a single-source coating precursor, which provides a highly-uniform coating, accurate control of coating thickness and metal stoichiometry.
H01M 4/52 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de nickel, de cobalt ou de fer
H01M 4/583 - Matériau carboné, p.ex. composés au graphite d'intercalation ou CFx
H01M 4/62 - Emploi de substances spécifiées inactives comme ingrédients pour les masses actives, p.ex. liants, charges
The present invention provides A porous scaffold membrane configured for use in a well plate insert, method of making the insert, an apparatus comprising the inset and uses of the insert in monitoring cell culture.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
In a method for preparing a hyperpolarised sample, for example for carrying out a magnetic resonance technique, the sample is formed as a frozen layer (4) of a starting solution on a surface of a thermoconductive sample holder (1,2). The solution comprises molecules for hyperpolarisation, and photo-reactive molecules. Free radicals are induced in the frozen layer by exposing it to radiation. The sample is then hyperpolarised by dynamic nuclear polarization at a dynamic nuclear polarization temperature. After hyperpolarisation, the temperature of the sample is raised to a thermalisation or quenching temperature by thermal conduction of heat through the sample holder, to quench the free radicals. The polarised sample may then be stored for use, retaining its polarisation.
G01R 33/28 - Dispositions ou appareils pour la mesure des grandeurs magnétiques faisant intervenir la résonance magnétique - Détails des appareils prévus dans les groupes
G01R 33/62 - Dispositions ou appareils pour la mesure des grandeurs magnétiques faisant intervenir la résonance magnétique utilisant la résonance double
G01N 24/12 - Recherche ou analyse des matériaux par l'utilisation de la résonance magnétique nucléaire, de la résonance paramagnétique électronique ou d'autres effets de spin en utilisant la résonance double
In a method for preparing a hyperpolarised sample, for example for a magnetic resonance procedure, a starting solution comprising alpha-ketoglutaric acid and 13C-labelled molecules is frozen to form a frozen solution. The solution is irradiated with ultraviolet and/or visible radiation, to generate free radicals. The frozen solution is then hyperpolarised by applying a magnetic field to the solution while irradiating it with frequency-modulated microwave radiation.
G01R 33/28 - Dispositions ou appareils pour la mesure des grandeurs magnétiques faisant intervenir la résonance magnétique - Détails des appareils prévus dans les groupes
G01R 33/62 - Dispositions ou appareils pour la mesure des grandeurs magnétiques faisant intervenir la résonance magnétique utilisant la résonance double
G01N 24/12 - Recherche ou analyse des matériaux par l'utilisation de la résonance magnétique nucléaire, de la résonance paramagnétique électronique ou d'autres effets de spin en utilisant la résonance double
G01R 33/56 - Amélioration ou correction de l'image, p.ex. par des techniques de soustraction ou d'établissement de moyenne
The present invention relates to the field of brain tumour treatment. The invention provides methods of killing brain tumour cells in these tissues using high concentrations of cytotoxic agents which are capable of binding strongly to normal brain extracellular matrix (ECM), but less strongly to extracellular matrix components in the tumour environment. The cytotoxic agent is a polyamine, e.g. spermidine or putrescine.
IuIΓvv, of the fluid. The modelled flow field is compressed by representing the flow field with the shape of the boundary, the kinematic viscosity, and inlet and/or outlet boundary conditions where an inlet and/or outlet exists.
The present invention relates to antibody conjugates, and methods of manufacturing the same. In particular, the present invention relates to a conjugate comprising an antibody, a linker and at least one active agent, wherein: the linker connects the at least one active agent(s) to the antibody; ii) the linker is attached to the antibody through 5 to 8 independent covalent bonds; and iii) each covalent bond between the linker and the antibody is formed from the reaction between a sulfur atom on the antibody and a functional group on the linker.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
The present invention relates to zeolite bodies, in particular those having improved physical and chemical properties, methods of manufacturing said zeolite bodies, and uses of said zeolite bodies, in particular in catalysis and gas separation.
C01B 39/40 - Type ZSM-5 utilisant au moins un agent structurant organique
B01J 20/00 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation
B01J 29/00 - Catalyseurs contenant des tamis moléculaires
C01B 39/46 - Autres types caractérisés par leur diagramme de diffraction des rayons X et par leur composition définie
C01B 39/48 - Autres types caractérisés par leur diagramme de diffraction des rayons X et par leur composition définie utilisant au moins un agent structurant organique
67.
PROCESS FOR THE COMBINED MANUFACTURE OF STEEL AND CEMENT CLINKER
A process is disclosed for the combined manufacture of steel and cement clinker. Steel scrap is loaded in an electric arc furnace for forming molten steel. Cement paste derived from construction and demolition waste is loaded in the electric arc furnace to act as a flux for the steel to assist in the removal of impurities from the molten steel and forming an electric arc furnace slag. The heat of the molten steel promotes clinkering of the electric arc furnace slag to form clinkered electric arc furnace slag. The clinkered electric arc furnace slag is removed from the electric arc furnace.
The present application features methods of treating schizophrenia and bipolar disorder by targeting dysregulated novel open reading frames (nORF) in which increased or reduced expression of the dysregulated nORF is associated with the schizophrenia or bipolar disorder.
A61P 25/18 - Antipsychotiques, c. à. d. neuroleptiques; Médicaments pour le traitement de la manie ou de la schizophrénie
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
69.
STAIN-FREE DETECTION OF EMBRYO POLARIZATION USING DEEP LEARNING
Disclosed herein include systems, devices, and methods for detecting embryo polarization from a 2D image generated from a 3D image of an embryo that is not fluorescently labeled using a convolutional neural network (CNN), e.g., deep CNN.
The present disclosure relates to a device for pre-processing image data, for instance, for Computer Vision (CV) applications. The device is configured to obtain, by means of a channel, image data of an image sensor. The image data comprises an intensity value for each of a plurality of image sensor pixels associated with the channel. The device is further configured to determine, in a logarithmic domain, a histogram of the image data based on a noise profile of the image sensor. The histogram comprises a plurality of bins, wherein each bin from the plurality of bins is associated with a set of intensity values of the image data. The device is further configured to determine a Transfer Function (TF) based on the histogram of the image data. The device may be further configured to pre-process the image data based on the TF, before providing it to the CV application.
The present invention provides a computer-implemented method for analysing a urine sample from a subject. The method comprises providing the value of one or more cell-free DNA fragment size metrics for said sample, and determining whether the sample has a high or low likelihood of being from a brain cancer patient by providing said values of said cell-free DNA fragment size metrics as input to a machine learning model. The machine learning model is trained to classify sample data into one of at least two classes, the at least two classes comprising a first class having a high likelihood of being from a brain cancer patient and a second class having a low likelihood of being from a brain cancer patient. Methods for diagnosing or screening for brain cancer, detecting recurrence or residual disease, providing a prognosis or selecting a treatment for brain cancer are also described.
G16B 20/20 - Détection d’allèles ou de variantes, p. ex. détection de polymorphisme d’un seul nucléotide
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
The invention provides a method for identifying a modified cytosine residue, which may be 5-methylcytosine or 5-hydroxymethylcytosine, in a nucleotide sequence. The method comprises oxidising the modified cytosine residue through a non-enzymatic, one-electron process to form 5-formylcytosine. The presence of 5-formylcytosine can be established by labelling and identifying this residue. The invention also provides a method of modifying a polynucleotide containing a 5-methylcytosine and/or a 5-hydroxymethylcytosine residue, a method of oxidising 5-methylcytosine, 5-hydroxymethylcytosine, a 5-methylcytosine residue, or a 5-hydroxymethylcytosine residue, use of a non-enzymatic radical initiator to oxidise a 5-methylcytosine or 5-hydroxymethylcytosine residue, and a kit for use in the methods.
This invention related to methods of adapting or modifying a complementary DNA (cDNA) sequence for expression in a eukaryotic cell. A nucleic acid molecule is provided that comprises a cDNA sequence that includes two or more splicing consensus motifs that divide the cDNA sequence into exon regions of 50 to 1200 nucleotides. Heterologous introns are then inserted into the splicing consensus motifs of the cDNA sequence, wherein each heterologous intron comprises a 3' region having a GC content that is equal to or lower than the GC content of a 5' region of the immediately downstream exon region. This produces a nucleic acid molecule comprising a modified cDNA sequence for expression in a eukaryotic cell. Methods, recombinant nucleic acid comprising a cDNA sequence, expression vectors comprising the recombinant nucleic acid and eukaryotic cells comprising a recombinant nucleic acid or expression vector are provided.
C12N 15/67 - Méthodes générales pour favoriser l'expression
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
74.
TREATMENT OR PREVENTION OF ISCHAEMIA REPERFUSION INJURY
The present invention relates to compositions for use in treating or preventing ischaemia reperfusion injury. In particular, the present invention relates to a composition comprising a salt of formula (I): for use in treating or preventing ischaemia reperfesion injury in a subject; wherein said composition has a pH of from about 4.0 to about 7.0. and wherein X, Y, n, m, Z, A and B are as defined herein.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
This invention relates to the modulation of angiotensin converting enzyme 2 (ACE2) expression by the farnesoid X receptor (FXR). Provided are methods of treatment of an angiotensin converting enzyme 2 (ACE2) mediated disease in an individual and methods of reducing the susceptibility of an individual to an ACE2 mediated disease by reducing the activity or expression of farnesoid X receptor (FXR) in the individual. ACE2 mediated diseases include infection with ACE2 binding viruses, such as Sars-CoV-2. The activity or expression of FXR may be reduced by administering an FXR inhibitor such as z-guggulsterone (ZGG) or ursodeoxycholic acid (UDCA) to the individual. Assays, in vitro methods and screening methods are also provided.
A61K 31/568 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes non substitués en position 17 bêta par un atome de carbone, p.ex. œstrane, œstradiol substitués en positions 10 et 13 par une chaîne ayant au moins un atome de carbone, p.ex. androstane, testostérone
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrène; Leurs dérivés, p.ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p.ex. cholane, cholestane, ergostérol, sitostérol
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
76.
IMPROVEMENTS IN AND RELATING TO ENCODING AND COMPUTATION ON DISTRIBUTIONS OF DATA
A computer-implemented method for the encoding of, and computation on, distributions of data, the method comprising: obtaining a first set of data items; obtaining a second set of data items; generating a first tuple containing parameters encoding a probability distribution characterising the distribution of the data items of the first set; generating a second tuple containing parameters encoding a probability distribution characterising the distribution of the data items of the second set in which the parameters used to encode the distribution of the data items of the second set are the same as the parameters used to encode the distribution of the data items of the first set; generating a third tuple using parameters contained within the first tuple and using parameters contained within the second tuple, the third tuple containing parameters encoding a probability distribution representing the result of applying an arithmetic operation on the first probability distribution and the second probability distribution; outputting the third tuple.
G06F 7/544 - Méthodes ou dispositions pour effectuer des calculs en utilisant exclusivement une représentation numérique codée, p.ex. en utilisant une représentation binaire, ternaire, décimale utilisant des dispositifs non spécifiés pour l'évaluation de fonctions par calcul
G06F 16/2458 - Types spéciaux de requêtes, p.ex. requêtes statistiques, requêtes floues ou requêtes distribuées
77.
IMPROVEMENTS IN AND RELATING TO MEASUREMENT APPARATUSES
A computer-implemented method for sampling data from a measurement device for representing uncertainty in measurements made by the measurement device, the method comprising: obtaining a data set comprising time-sequential data elements generated by the measurement device; and: (a) calculating a statistic of a sub-set of data elements consecutive within the data set; (b) comparing the value of the statistic to a reference value; and, (c) if the value of the statistic differs from the reference value by less than a threshold amount, then: modifying the sub-set by appending to the sub-set at least one additional data element which is subsequent to the sub-set; and, repeating steps (a) to (c) for the modified sub-set of data elements; (d) if the value of the statistic differs from the reference value by more than said threshold amount, then: outputting the sub-set collectively as a sample set of data elements generated by the measurement device for representing uncertainty in measurements made by the measurement device; repeating steps (a) to (d) in respect of a subsequent sub-set of data elements consecutive within the data set.
A method for computation on distributions of data, the method comprising providing a microarchitecture comprising: a first register containing data items; a second register containing distribution data representing distributions that are uncertainty representations associated with respective said data items; a first arithmetic logic unit for executing arithmetic on data items selected from the first register; a second arithmetic logic unit for executing arithmetic on distribution data selected from the second register; the method comprising the following steps implemented by the microarchitecture: executing, by the first arithmetic logic unit, an arithmetic operation on data items selected from the first register, and outputting the result; executing, by the second arithmetic logic unit, an arithmetic operation on distribution data representing distributions selected from the second register that are associated with the data items selected from the first register, and outputting the result; wherein the arithmetic operation executed on the distribution data selected from the second register is the same as the arithmetic operation executed on the data items selected from the first register thereby to generate further distribution data representing uncertainty associated with result of the arithmetic operation executed on the data items selected from the first register.
G06F 9/30 - Dispositions pour exécuter des instructions machines, p.ex. décodage d'instructions
G06F 17/17 - Opérations mathématiques complexes Évaluation de fonctions par des procédés d'approximation, p.ex. par interpolation ou extrapolation, par lissage ou par le procédé des moindres carrés
79.
METHOD AND SYSTEM FOR ROBOT NAVIGATION IN UNKNOWN ENVIRONMENTS
Broadly speaking, embodiments of the present techniques provide methods and systems for robot navigation in an unknown environment. In particular, the present techniques provide a navigation system comprising a navigating device and a sensor network comprising a plurality of static sensors. The sensor network is trained to predict a direction to a target object, and the navigating device is trained to reach the target object as efficiently as possible using information obtained from the sensor network.
This invention relates to somatic expansion inhibitors, to methods of producing the same and to therapeutic applications thereof. More specifically, the invention relates to MLH1 inhibitors and FAN1 derived nucleases for treating, preventing or delaying the onset of repeat expansion diseases.
A61K 38/16 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
A61P 25/14 - Médicaments pour le traitement des troubles du système nerveux pour traiter les mouvements anormaux, p.ex. chorée, dyskinésie
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
This invention relates to antibodies that bind to and inhibit the activity of glial cell-derived neurotrophic factor family receptor alpha like (GFRAL) protein. The invention also relates to the GDF15-GFRAL signalling pathway as a therapeutic target for states of cachexia and conditions involving reduction in food intake and reduction in muscle and fat mass.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
A microscopic imaging method comprising: illuminating a three-dimensional object with a light sheet generated by an illumination optical system and capturing light-field information of the illuminated object with an imaging optical system.
The invention provides a method of characterising a DNA sample obtained from a tumour, the method including the steps of: determining the value of one or more mutational signature metrics for the sample, wherein the mutational signature metrics are selected from: exposure of one or more mutational signatures of mismatch repair (MMR), similarity between the substitution profile of the sample and that of one or more MMR gene knockouts, the number of repeat mediated indels in the mutational profile of the sample, and the similarity between the repeat mediated deletion profile of the sample and that of one or more MMR gene knockouts; and based on said values of said one or more mutational signature metrics, classifying said sample between a class associated with a high likelihood of being mismatch repair (MMR)-deficient and a class associated with a low likelihood of being MMR-deficient. Identification of a tumour as MMR-deficient may be used to inform treatment choices, for example treatment with an immune therapy such as a checkpoint inhibitor, and for providing a prognosis.
ÖSTERREICHISCHE AKADEMIE DER WISSENSCHAFTEN (Autriche)
Inventeur(s)
Greer, Alan Lindsay
Ivanov, Iurii
Eckert, Jürgen
Sarac, Baran
Abrégé
A method of making a solid material by solidification from a melt is provided. The melt contains Fe, Ni, and one or more additives Z, such that the solid material comprises a phase having an L10 structure, and the proportion of the one or more additives Z in the L10 phase is lower than the proportion of Z in the melt. A method of making a magnet comprises the steps of solidifying the melt, isolating the L10 phase, and forming the magnet from the L10 phase. A magnetic solid material comprising an L10 structure and a magnet are also provided.
H01F 1/06 - Aimants ou corps magnétiques, caractérisés par les matériaux magnétiques appropriés; Emploi de matériaux spécifiés pour leurs propriétés magnétiques en matériaux inorganiques caractérisés par leur coercivité en matériaux magnétiques durs métaux ou alliages sous forme de particules, p.ex. de poudre
H01F 1/08 - Aimants ou corps magnétiques, caractérisés par les matériaux magnétiques appropriés; Emploi de matériaux spécifiés pour leurs propriétés magnétiques en matériaux inorganiques caractérisés par leur coercivité en matériaux magnétiques durs métaux ou alliages sous forme de particules, p.ex. de poudre comprimées, frittées ou agglomérées
H01F 41/02 - Appareils ou procédés spécialement adaptés à la fabrication ou à l'assemblage des aimants, des inductances ou des transformateurs; Appareils ou procédés spécialement adaptés à la fabrication des matériaux caractérisés par leurs propriétés magnétiques pour la fabrication de noyaux, bobines ou aimants
C22C 33/04 - Fabrication des alliages ferreux par fusion
Provided are compounds of the Formula I, and salts, hydrates and solvates thereof: wherein R1, Q, Ra, Rb, Rc, Rd and Re are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein, to processes for synthesising these compounds and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. quinolizines, naphtyridines, berbérine, vincamine
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
The invention provides a method for determining the state of charge (SOC) of an electrolyte, such as an electrolyte within a flow battery, by measuring the bulk magnetic susceptibility of the electrolyte. The method includes the step of measuring the magnetic susceptibility of an electrolyte in a measurement region and determining the state of charge of the electrolyte based on the magnetic susceptibility of the electrolyte.
H01M 8/18 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments à combustible; Leur fabrication Éléments à combustible à régénération, p.ex. batteries à flux REDOX ou éléments à combustible secondaires
G01R 31/36 - Dispositions pour le test, la mesure ou la surveillance de l’état électrique d’accumulateurs ou de batteries, p.ex. de la capacité ou de l’état de charge
G01R 31/392 - Détermination du vieillissement ou de la dégradation de la batterie, p.ex. état de santé
in vitroin vitro that comprise culturing the cholangiocytes in the presence of a farnesoid X receptor (FXR) agonist, such as chenodeoxylic acid (CDA) or obeticholic acid (OCA). The FXR-treated cholangiocytes and organoids obtained by the methods may be useful for example for the treatment of biliary disorders and compound screening. Also provided are kits and uses of culture media for the production of FXR-treated cholangiocyte organoids.
in vitro in vivo in vivo methods for engrafting liver cells, such as cholangiocytes, into a liver comprising administering the liver cells to the biliary tree of the liver. The liver cells may be in the form of aggregates and may be administered in the direction of decreasing biliary duct diameter. This may be useful for example for the treatment of an individual with a diseased or damaged liver.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
The invention relates to formulations comprising niclosamide, or a pharmaceutically acceptable salt thereof, and a cyclodextrin for use in the treatment or prevention of a respiratory viral infection in a subject wherein the subject is undergoing dialysis, a kidney transplant recipient, or has vasculitis, an auto-immune kidney disease or glomerulonephritis; and wherein the formulation is administered to the subject intranasally.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/20 - Composés organiques, p.ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p.ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. carbomères
A61K 47/50 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
90.
IMPROVEMENTS IN OR RELATING TO A METHOD OF ANALYSING A COMPONENT IN A SAMPLE
A method of determining diffusion coefficient of one or more components in a polydisperse sample is provided. The method comprising the steps of: introducing an auxiliary fluid flow into a fractionation channel; introducing the polydisperse sample comprising one or more components into the fractionation channel; allowing the sample and the auxiliary fluid to create a combined flow; fractionating the combined flow into two or more fractions by diffusive sizing; subsequently separating two or more components from each fraction by creating a distribution of the components within a separation channel; detecting a characteristic of each the two or more components in each fraction; and comparing the characteristic of each component in each fraction in order to determine the diffusion coefficient of each of the one or more components in the polydisperse sample.
G01N 13/00 - Recherche des effets de surface ou de couche limite, p.ex. pouvoir mouillant; Recherche des effets de diffusion; Analyse des matériaux en déterminant les effets superficiels, limites ou de diffusion
This invention relates to an RNA trans- splicing molecule (RTM) that targets human endogenous retrovirus (HERV) pre-mRNA. The RTM comprises (i) a binding region specific for a HERV pre-mRNA, (ii) a trans- splicing splice domain and (ill) a coding sequence for a suicide protein. The binding region of the RTM binds to HERV pre-mRNA in a cell, such that the coding sequence is trans- spliced through the trans- splicing domain with the HERV pre-mRNA, resulting in a chimeric mRNA causing the suicide protein to be expressed in the cell. RTMs of the invention may be useful in selectively killing cells that express HERV genes, for example cancer cells. RTMs, encoding nucleic acids, methods of treatment and associated methods and uses are provided.
The present invention relates to a method of preparing a biological sample for electron microscopy, wherein the sample comprises a target nucleic acid, the method comprising (i) incubating an electron permeable substrate with an aqueous solution comprising an oligonucleotide probe; (ii) incubating the biological sample with the primed substrate; and (iii) washing the hybridised primed substrate. The invention also relates to a primed electron permeable substrate, and to the use of such a substrate.
BRITISH TELECOMMUNICATIONS PUBLIC LIMITED COMPANY (Royaume‑Uni)
Inventeur(s)
Al Rawi, Anas
Molnar, Daniel
Payne, Michael Christopher
Abrégé
A Goubau transmission line (1) for propagating a surface electromagnetic wave. A first transmission line part (11) and a second transmission line part is each configured for propagating the surface electromagnetic wave and each comprises a conductive material located upon a surface of a dielectric substrate (ε). The first transmission line part is separate from the second transmission line part and extends alongside the second transmission line part to be spaced therefrom by a transverse spacing (d). Within the transverse spacing an electric field generated by the first transmission line part by the propagation of the surface electromagnetic wave interacts with an electric field generated concurrently by the second transmission line part by the propagation of the surface electromagnetic wave. This interaction concentrates the electric field of the surface wave at parts of a dielectric substrate underlying the first and second transmission line parts.
Techniques for driving a directly modulated laser whilst correcting non-linearities an optical output waveform, based on generating a modulating current waveform that approximates an ideal modulating current that produces a linear optical output waveform. The techniques enable useful, practical approximations to the ideal modulating current to be determined.
H04B 10/50 - Systèmes de transmission utilisant des ondes électromagnétiques autres que les ondes hertziennes, p.ex. les infrarouges, la lumière visible ou ultraviolette, ou utilisant des radiations corpusculaires, p.ex. les communications quantiques Émetteurs
H04B 10/58 - Compensation pour sortie d’émetteur non linéaire
95.
METHOD OF TREATMENT OF MALARIA BY TARGETING OPEN READING FRAMES
The present application features methods of diagnosing treating malaria by targeting novel open reading frames in Plasmodium falciparum. The novel open reading frames (nORFs) associated with malaria are expressed in a mosquito and in a human.
EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) (Allemagne)
Inventeur(s)
Bateman, Alex
Bradley, John
Wang, Jun
Abrégé
This invention relates to the inhibition of the proliferation and/or activation of T cells by full-length factor V (FV) protein and peptides derived from full-length FV protein. This may be used to exert an immunosuppressive effect in therapy. FV peptides and proteins and their use in the treatment of autoimmune disorders and other conditions characterised by T cell mediated immune responses are provided.
INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY (Inde)
Inventeur(s)
Prabakaran, Sudhakaran
Abrégé
The present application features methods of treating a cancer associated with a dysregulated novel open reading frame (nORF) in which increased or reduced expression of the dysregulated nORF is associated with cancer.
INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY (Inde)
Inventeur(s)
Prabakaran, Sudhakaran
Abrégé
The present application features methods of treating a cancer associated with a genetic variant. The genetic variant is also present within a novel open reading frame (nORF) associated with the gene in which the variant leads to increased or reduced expression of the variant nORF.
The present application relates to metal–organic framework (MOF) nanoparticles, in particular,coated MOF nanoparticles, methods of manufacturing said coated MOF nanoparticles, and uses of said coated MOF nanoparticles.
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine liés à un système carbocyclique condensé, p.ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
100.
TREATMENT OF DISEASES ASSOCIATED WITH VARIANT NOVEL OPEN READING FRAMES
INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY (Inde)
Inventeur(s)
Prabakaran, Sudhakaran
Abrégé
The present application features methods of treating a disease associated with a genetic variant. The genetic variant is also present within a novel open reading frame (nORF) associated with the gene in which the variant encodes either the gain or loss of a stop codon.
brevets
